1. MIRA announced Phase 1 trial approval for Ketamir-2 focused on neuropathic pain. 2. Recruitment for clinical trial slated to start Q1 2025 in Israel.
Successful clinical trials often lead to stock appreciation; historical examples include other biotech firms whose initial trials significantly boosted their stock prices post-approval.
The initiation of clinical trials is pivotal for biotech firms, potentially attracting investments and boosting market confidence in MIRA.
The announcement and commencement of trials can lead to immediate investor interest, similar to previous biotech milestones.